Your session is about to expire
← Back to Search
Daratumumab for Multiple Myeloma
Study Summary
This trial is testing a new cancer drug on patients with a specific type of blood cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 1 & 2 trial • 22 Patients • NCT02841033Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't used specific myeloma treatments or high-dose steroids recently.My multiple myeloma needs treatment.I haven't had cancer, except for certain skin, cervical, or early-stage cancers, in the last 3 years.I was diagnosed with smoldering multiple myeloma less than 5 years ago.I have been diagnosed with AL amyloidosis.I have been diagnosed with COPD or severe asthma in the last 2 years.I am fully active or restricted in physically strenuous activity but can do light work.My condition is diagnosed as intermediate or high-risk smoldering multiple myeloma.
- Group 1: Arm A (Long Intense)
- Group 2: Arm C (Short Intense)
- Group 3: Arm B (Intermediate)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How widespread is this trial's implementation?
"This research trial is being administered at 18 sites across the country, including major cities like Cincinnati, Little Rock and Nashville. To keep travel to a minimum when participating in this study, please select the site closest to you."
Could you provide an overview of the prior experiments involving daratumumab?
"Currently, there are 140 studies researching daratumumab. Of those active trials, 26 have been classified as Phase 3. The primary research hub is Harrison, New york; however, the drug's clinical trial presence spans 5561 different locations worldwide."
Are there any available opportunities for recruitment into this trial?
"According to the records on clinicaltrials.gov, this trial has concluded its search for participants and is no longer recruiting applications. The initial posting of this research was made on May 20th 2015, with a final update taking place November 3rd 2022. Despite the status quo of this study, there are still 948 other medical trials that are actively searching for volunteers at present time."
How many subjects are participating in this clinical investigation?
"Unfortunately, recruitment for this clinical trial has ceased. It was initially posted on May 20th 2015 and last updated November 3rd 2022. However, there are 808 trials enrolling patients with multiple myeloma and 140 daratumumab studies currently admitting participants."
What evidence is there to suggest that daratumumab has a low risk of adverse effects?
"Our team at Power assigned daratumumab a safety rating of 2, as the data for this Phase 2 trial suggests it is safe to use but does not demonstrate efficacy."
What medical conditions are most often treated with daratumumab?
"Daratumumab is typically prescribed as a biological response modifier. Additionally, it can be employed to combat cases of refractory multiple myeloma, relapsed or refractory multiple myeloma, and in conjunction with cell transplants."
Share this study with friends
Copy Link
Messenger